Literature DB >> 7000415

Airway and metabolic resistance to intravenous salbutamol: a study in normal man.

S T Holgate, W A Stubbs, P J Wood, E S McCaughey, K G Alberti, A E Tattersfield.   

Abstract

1. The airway and metabolic responses to an intravenous beta 2-agonist salbutamol have been investigated in normal subjects before and after chronic administration of inhaled salbutamol, 1600 micrograms daily for 2 weeks. 2. Before chronic inhalation of salbutamol there was a dose-dependent increase in specific airway conductance after intravenous salbutamol in cumulative doses from 25 to 300 micrograms. 3. Measurement of concentrations of blood glucose, lactate, pyruvate, glycerol, ketone bodies, non-esterified fatty acids, insulin, plasma cyclic AMP and cyclic GMP were made after each increment of salbutamol and all showed an increase apart from cyclic GMP. 4. After chronic inhalation of salbutamol there was a decrease in the airway, metabolic and insulin response to intravenous salbutamol. The cyclic AMP response showed little change. 5. This study confirms the development of adrenergic resistance in the airways of normal subjects after large does of inhaled salbutamol and shows that this is associated with widespread metabolic adrenergic resistance.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7000415     DOI: 10.1042/cs0590155

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  15 in total

1.  Potentiation of the adverse effects of intravenous terbutaline by oral theophylline.

Authors:  S R Smith; M J Kendall
Journal:  Br J Clin Pharmacol       Date:  1986-04       Impact factor: 4.335

2.  Dose-response curves to inhaled beta-adrenoceptor agonists in normal and asthmatic subjects.

Authors:  P J Barnes; N B Pride
Journal:  Br J Clin Pharmacol       Date:  1983-06       Impact factor: 4.335

3.  Modification of the thermogenic effect of acutely inhaled salbutamol by chronic inhalation in normal subjects.

Authors:  S R Wilson; P Amoroso; J Moxham; J Ponte
Journal:  Thorax       Date:  1993-09       Impact factor: 9.139

4.  Does tachyphylaxis occur to the non-pulmonary effects of salmeterol?

Authors:  J G Maconochie; N A Minton; J E Chilton; O N Keene
Journal:  Br J Clin Pharmacol       Date:  1994-02       Impact factor: 4.335

5.  Sublingual isoprenaline in treatment of primary pulmonary hypertension: discussion paper.

Authors:  J F Ackroyd
Journal:  J R Soc Med       Date:  1985-06       Impact factor: 5.344

6.  Airway response to salbutamol: effect of regular salbutamol inhalations in normal, atopic, and asthmatic subjects.

Authors:  J E Harvey; A E Tattersfield
Journal:  Thorax       Date:  1982-04       Impact factor: 9.139

7.  Increased airway reactivity in the guinea-pig follows exposure to intravenous isoprenaline.

Authors:  S Sanjar; A Kristersson; L Mazzoni; J Morley; E Schaeublin
Journal:  J Physiol       Date:  1990-06       Impact factor: 5.182

8.  Effects of the beta 2-adrenoceptor antagonist ICI 118,551 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man.

Authors:  J M Arnold; P C O'Connor; J G Riddell; D W Harron; R G Shanks; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1985-05       Impact factor: 4.335

9.  Occupational asthma in salbutamol process workers.

Authors:  R M Agius; A G Davison; E R Hawkins; A J Newman Taylor
Journal:  Occup Environ Med       Date:  1994-06       Impact factor: 4.402

10.  The assessment of the beta-adrenoceptor blocking activity and cardioselectivity of Koe 3290 in normal subjects.

Authors:  T H Pringle; A J McNeill; J G Riddell; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1987-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.